Pictet Asset Management Holding SA Has $22.27 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Pictet Asset Management Holding SA decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 6.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 450,764 shares of the specialty pharmaceutical company’s stock after selling 32,635 shares during the quarter. Pictet Asset Management Holding SA owned about 0.78% of Supernus Pharmaceuticals worth $22,269,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares during the period. Torren Management LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $49,000. EverSource Wealth Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $51,000. Hantz Financial Services Inc. raised its holdings in shares of Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth approximately $55,000.

Supernus Pharmaceuticals Stock Up 1.9%

NASDAQ:SUPN opened at $47.41 on Thursday. Supernus Pharmaceuticals, Inc. has a 12-month low of $31.35 and a 12-month high of $59.68. The stock’s fifty day simple moving average is $47.24 and its 200-day simple moving average is $49.51. The firm has a market capitalization of $2.75 billion, a P/E ratio of -92.96, a P/E/G ratio of 0.99 and a beta of 0.54.

Analyst Ratings Changes

Several brokerages recently issued reports on SUPN. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Supernus Pharmaceuticals has an average rating of “Hold” and an average target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.